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Abstract. Melanomas are malignant tumours with high 
metastatic potential. The genetic alterations which lead to the 
transformation and progression of melanocytes to malignant 
melanoma remain obscure. Mutations in the ras gene family 
have been described, however their role in melanoma 
pathogenesis is still controversial. In this study we examined 
the incidence of H-, K- and N-ras mutations in 47 DNA 
samples isolated from paraffin-embedded 25 cutaneous and 
22 uveal malignant melanoma tissues and a MeWo 
melanoma cell line using the Restriction Fragment Length 
Polymorphism (RFLP) analysis of PCR products. Only one 
mutation in codon 61 of the N-ras gene was found 
suggesting that the importance of ras mutations in melanoma 
tumourigenesis may be limited. 
Introduction 
Carcinogenesis is considered to be a complex multistep 
process (1,2). Evidence from epidemiological studies in man 
and biochemical and histopathological observations of 
tumours in vitro and in vivo suggest that chemicals, radiation 
and viruses are involved in the initiation of the malignancy. 
These factors could alter, directly or indirectly, the 
expression of specific genes, namely oncogenes and onco­
suppressor genes and affect the machinery regulating normal 
growth, differentiation and programmed cell death, leading to 
malignant transformation (2). 
The ras gene family is frequently found to be deregulated 
in tumours. It consists of many related genes which share the 
characteristic of signal transduction. Among them, the H-ras, 
K-ras and N-ras are the most well-characterized and studied 
(3). The three genes encode for highly homologous proteins 
Correspondence to: Professor D.A. Spandidos, Institute of 
Biological Research and Biotechnology, National Hellenic 
Research Foundation, 48 Vas. Constantinou Avenue, Athens 116 35. 
Greece 
Key words: ras mutations, uveal melanoma, cutaneous melanoma 
(p21 ras) which are localized at the inner side of the cell 
membrane and present GTPase activity. 
Genetic defects characterizing the ras genes include 
amplification and loss of a normal ras allele, but the 
commonest alterations involve point mutations in codons 12, 
13 and 61 of the H-, K-, and N-ras genes. 
The selective growth advantage confered by ras gene 
mutations has been demonstrated in cell systems in vitro and 
mouse models. Chemical carcinogens have been shown to 
induce skin papillomas in mice with high percentage of 
activated H-ra.v (4) while transfection of early passage rodent 
cells with the mutant Η-ras leads to malignant conversion by 
causing multiple metastasis when injected in nude mice (5,6). 
Furthemore, mutations in the ras genes have been described 
in a large range of human tumours (7,8). 
Melanomas are malignant tumours with high metastatic 
potential. Both intrinsic and extrinsic risk factors have been 
discussed and studied as a possible etiology for the initiation 
and development of this type of tumour (9). Genetic factors 
may play a role, since differential incidence of melanomas 
has been found in different ethnic groups and family history 
can be a risk parameter. Furthermore, extrinsic factors, such 
as ultraviolet (UV) radiation, are considered as major causes 
of melanomas (10). 
The role of ras oncogenes in the pathogenesis of 
malignant melanomas remains paradoxical (11,12). The 
incidence of ras mutations in particular is a subject of debate 
due to controversial data that emphasizes the confusing 
nature of ras gene alterations and the melanoma 
tumourigenesis. 
In order to examine this question we studied the incidence 
of H- and K-ras mutations in codon 12 and of the N-ras 
mutations in codon 61 using the Polymerase Chain Reaction 
(PCR) followed by Restriction Fragment Length 
Polymorphism (RFLP) analysis in 47 melanomas and a 
MeWo human melanoma cell line. 
Materials and methods 
Clinical specimens and cell lines. The 22 paraffin uveal 
melanoma blocks were obtained from the Institute for Cancer 
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9 Η-ras oncogene sequence with wild type codon 12 
5'GAGACCCTGTAGGAGGACCCCGG GGCGCCGGCGGT AGTCCCTCGTCTCAGCACCC..3' 
5' GAGACCCTGTAGGAGGACCC 3' 3'TCAGGGAGCAGAGTCGTGGG 5' 
H5'primer (1620-1640) H3'primer (1912-1932) 
• 
PCR amplification 
5' GAGACCCTGTAGGAGGACCCCGG GGCGCCGGCGGT AGTCCCTCGTCTCAGCACCC 3' 
PCR product (312bp) 
• 
Msp I digestion 
5' GAGACCCTGTAGGAGGACCC 3- 5' CGG....GGCGC 3' 5'CGGCGGT..AGTCCCTCGTCTCAGCACCC 3' 
21 bp 55bp 236bp 
Digestion's products 
Mspl site: c'cGG 
K-ras oncogene sequence with wild type codon 12 
.. 5'ATG ACTG AAT AT AAACTTGTGGTAGTTGG AGCTGGT GGC ATATTACTGGTGC AGG ACC ATTCTTTGA TAC AG A3'. 
5' ACTGAATATAAACTTGTGGTAGTTGGAÇCT 3' 3' CCAGGTCCTGGTAAGAAACT 5' 
K5' primer (6410-6439) K3' Pr"™' (6547-6566) 
f PCR Amplification 
5' ACTGAATATAAACTTGTGGTAGTTGGACCTGGTGGC 5' ATATTACT GGTCCAGGACCATTCTTTGA 3' 
PCR product (157 bp) 
Τ 
BstNl digestion 
5'ACTGAATATAAACTTGTGGTAGTTGGACC 3' 5'TGGT GGC ATATTACTGGTCC3' 5'A GGACCATTCTTTGA 3' 
29 bp 113 bp 15bp 
Digestion products 
BstNl site: CC (An")GG 
N-ras oncogene wild type sequence 
5'TGTTTGTTGGACATACTGGATACAGCTGGAC GAGAGACCAATACATGAGGACAGGCGAAGGC 3'.. 
5' GACATACTGGATACAGCTGGC 3' 3' CTGGTTATGTACTCCTGTCC 5' 
N5 primer N6 primer 
w PCR Amplification 
5' GACATACTGGATACAGCTGGCCAGA GAGAGACCAATACATGAGGACAGG 3'.. 
PCR product (65 bp) 
• 
Mscl digestion 
5' GACATACTGGATACAGCTGGC 3' 5' CCAGAAG GAGAGACCAATACATGAGGACAGG 3' 
21 bp 44 bp 
Digestion products 
Τ 
Mscl site: TGG CCA 
Figure I. Schematic illustration of the detection of (a) H-ra.v codon 12. (b) K-ras codon 12 and(c) N-ras codon 61 mutations by PCR-RFLP analysis. 
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Studies, Sheffield, UK and the 25 cutaneous from the 
Medical School, University of Thrace, Alexandroupolis, 
Greece. Posterior uveal melanoma tissue was obtained 
following enucleation, fixed and embedded in paraffin wax, 
and processed for routine histological assessment. The 
samples included in this study were from ciliary and 
choroidal malignant melanomas. 
The MeWo cell line (13) as well as the EJ human bladder 
carcinoma, SW480 human colon cancer and the HL60 human 
myeloid leukemic cell lines were maintained in RMPI-10% 
FCS supplemented with 2 mM glutamine. 
DNA extraction. The paraffin-embedded tissues were put in 
1.5 ml tubes and 300 μΐ lysis solution containing 0.1 Ν 
NaOH/ 2M NaCl were added. Samples were then boiled for 5 
min and centrifuged at 13000 rpm for 5 min at 4"C. 
Supernatants were transferred into fresh tubes, extracted once 
with phenol/chloroform and once with chloroform alone and 
DNA was precipitated with the addition of 1 ml ethanol. 
DNA was recovered with centrifugation at 13000 rpm for 15 
min at 4"C washed with cold 70% ethanol and resuspended in 
20 μΐ distilled water. DNAs from the cell lines were isolated 
in a similar manner. 
Oligonucleotide primers and PCR amplification. The 
oligonucleotides for H-ra.v codon 12. K-ra.s codon 12 and N-
ras codon 13 shown in Fig. 1 have been previously described 
(14,15). 1-2 μΐ of the extracted DNA of each sample was 
amplified in a volume of 100 μΐ under the following 
conditions: 
Η-ras amplification: 10 mM Tris-HCI pH 8.3. 50 mM KCl. 
2.5 mM MgCl
:
, 0.001% gelatin. 200 μΜ of each dNTP, 500 
ng of each primer and 2.5 U Taq polymerase (Perkin Elmer 
Cetus). Amplification parameters were the following: 
Denaturation at 94"C for 1 min, primer annealing and 
extention at 68"C for 1 min. 35 cycles. 
K-ras amplification: 16.6 mM (NH4) 2 S0 4 . 10 mM ß-
mercaptoethanol. 6.7 mM MgCK. 67 mM Tris-HCI pH 8.8, 
1.7 mg BSA. 200 μΜ of each dNTP, 500 ng of each primer 
and 2.5 U Taq polymerase (Perkin Elmer Cetus). 
Amplification parameters were the following: Denaturation 
at 94"C for 40 sec, primer annealing at 60°C for 45 sec and 
extention at 72"C for 50 sec, increasing the extention time by 
1 sec per cycle, 40 cycles. 
N-ra.v amplification: 16.6 mM (NH4) 2 S0 4 . 10 mM. β-
mercaptoethanol, 6.7 mM MgCL. 67 mM Tris-HCI pH 8.8. 
1.7 nig BSA, 200 μΜ of each dNTP. 500 ng of each primer 
and 2.5 U Taq polymerase (Perkin Elmer Cetus). 
Amplification parameters were the following: Denaturation 
at 94"C for 40 sec, primer annealing at 55"C for 50 sec and 
extention at 72"C for 50 sec, 40 cycles. 
RFLP analysis. H-ra.v codon 12: 10-20 μΐ aliquots of the 
amplification products were digested O/N with 20 U Mspl. 
K-ras codon 12: 10-20 μΐ aliquots of the amplification 
products were digested for 3 h with 20 U BstNI. 
N-ras codon 61: 10-20 μΐ aliquots of the amplification 
products were digested O/N with 20 U Mscl. 
Enzymes were purchased from New England Biolabs and 
the conditions followed for digestions were those 
65 bp 
44 bp 
M 1 
Figure 2. N-ras amplification products digested with Mscl and 
electrophoresed through an 8% Polyacrylamide gel. Lane I: Undigested 
positive control (HL60 cell line) (65 hp). Lane 2: Positive control digested 
with Mscl. Lane 3: undigested PCR product. Lanes 4-8: Negative samples 
(44 hp). Lane 9: Positive sample. M: pBR322/Mspl DNA marker. 
Resistance to Mscl digestion suggests a mutated N-ra.v gene (codon 61 ). 
recommended by the supplier. Incubation temperatures were 
60"C for BstNI and 37"C for Mspl and Mscl. 
The EJ and the SW480 cells have mutant H- and K-ras 
alleles in codon 12 and the HL60 cell line has a mutated N-
ras codon 61 allele. PCR products from amplified DNA 
isolated from these cell lines were used as positive controls 
for the completion of the digestion with Mspl. BstNI and 
Mscl, respectively. 
Digestion products were electrophoresed through a 2% 
agarose gel (for H- and K-ra.s products) or an 8% native 
polyacryamide gel (for N-ra.v products). Gels were stained 
with ethidium bromide and photographed on a UV light 
transilluminator. 
Results and Discussion 
The role of oncogenes in melanoma tumourigenesis is still 
controversial. The incidence of ras mutations, in particular, is 
a subject of debate. Initial studies showed that approximately 
20% of cutaneous melanomas presented ras mutations, the 
majority of which was found in the N-ras gene (10,16). 
Furthermore, these mutations occured in or adjacent to 
dipyrimidine sites, which is a well known target for UV 
damage (10). Albino et al (17) found similar results in 
cultured melanoma cell lines although only 5-6% of non-
cultured primary and metastatic melanomas had mutated ra.v 
genes. Again, the N-ra.v codon 61 mutations were found to 
predominate. However, some reports argue the importance of 
N-ra.v in melanoma tumourigenesis. Mooy et al (18), failed 
to observe any N-ras mutations among the 29 DNA samples 
from uveal melanoma tested with asymmetric PCR and 
sequencing. Similarly. O'Mara et al (19) by studying 22 
melanoma short-term cell lines for N-ra.v mutations, 
identified only two, both found in codon 61 of the gene. 
Limited information is available on the molecular genetics of 
uveal melanomas. Increased myc expression has been 
reported and loss of heterozygosity of THRB and n/??23-Hl 
gene have been found (20,21 ). 
In our study, by using a PCR-RFLP (Restriction 
Fragment Length Polymorphism) method in 47 DNA 
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312 bp 
291 bp 
236 bp 
Figure 3. W-ras amplification products digested with Mspl and 
electrophoresed through a 2% agarose gel. Lanes 1-6: Negative samples 
(236 bp). Lane 7: Positive control (EJ cell line) (291 bp), Lane 8: undigested 
product (312 bp), M: pUC18/HaeIII DNA marker. 
157bp 
113 bp 
M 1 2 3 4 5 6 7 
Figure 4. K-ras amplification products digested with BstNI and 
electrophoresed through a 2% agarose gel. Lane 1 : Positive control (SW480 
cell line) (157 bp), Lanes 2-7: Negative samples (113 bp), M: pUC18/HaeIII 
DNA marker. 
samples isolated from paraffin-embedded sections of 22 
uveal and 25 cutaneous melanomas, we detected only one N-
ras codon 61 mutation (Fig. 2, lane 9) in a uveal melanoma. 
Wild type product (44 bp) was identified in this sample, 
indicating heterozygosity for the mutation, which is in 
agreement with a previous report (19). No N-ras mutations 
were found in the 25 cutaneous melanomas tested suggesting 
that the inc idence of N-ras muta t ions in this type of 
malignancy has been possibly overestimated, and similar 
results are shown for uveal melanomas. Uveal melanomas 
show very few cytogenetic abnormalities, compared with 
other solid tumours, and relatively little stromal tissue and 
cellular infiltration (22,23). The results of our study would 
therefore preclude a role for N-ras in the early events of 
tumourigenesis of melanoma. 
Fur thermore , we found no H- and K-ras codon 12 
mutations (Figs. 3 and 4), which is in agreement with some 
but not all previous reports on cutaneous melanomas. A high 
percentage of K-ras mutations was reported by Shukla et al 
(24) in 40 melanotic lesions, using oligodeoxynucleotide 
hybridization of PCR products. On the contrary, Albino et al 
(25), by following similar experimental procedure, found no 
mutations at codon 12 in the K-ras gene. We also failed to 
observe any ras mutation in the melanoma cell line Me Wo. 
The heterogeneity of factors which could contribute to the 
initiation and/or the development of melanomas could partly 
explain the marked discrepancy in the mutation frequencies 
observed. Although both our study and those of others 
suggest that mutations in ras genes are rare in melanomas, a 
possible role for ras for the development and/or progression 
of this type of malignancy should not be excluded. Long- but 
not short-term expression of the viral W-ras gene has been 
shown to induce a complete transformed phenotype in 
melanocytes, possibly via introduction of chromosomal 
instability (26). Additional factors such as paracrine and 
autocrine functions and their possible interaction with the 
ras-mediated signal transduction may also be important. 
Indeed, melanoma cells produce a variety of growth factors 
and growth factor receptors and fibroblast growth factor 
(FGF) appears to have an autocrine role (27). Since ras has 
been shown to mediate the signal of several growth factors, 
including that of FGF (28), the levels of the p21 ras protein 
could be important. Increased levels of p21 ras protein in 
melanoma cells, as compared to normal melanocytes were 
described by Tanikawa et al (29) although Albino et al (17) 
found no di f ference in ras p21 express ion be tween 
melanomas at different phases of growth or between those 
harboring a known ras mutation and those that did not. 
Finally, it has been suggested that mutated ras genes are 
more interactive with the machinery controlling melanocyte 
differentiation rather than transformation and ras gene 
mutations have been correlated with a subset of EGF receptor 
and Class II major histocompatibility (la) antigen positive 
melanomas from an early phase of differentiation (17). 
The complexity of the up-to-date information clearly 
suggest that a persistent and cautious approach must be 
followed in order to unravel the precise role of ras gene 
family in melanoma tumourigenesis. 
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